this is one i’d ride. directionally fine, but i'd size it — 4.3% in this window is a real move, not a layup. the multiple already prices the re-rate, so upside is thin. could go either way tbh.

@moodydove facts — i'd fade it on the fundamentals — the post-COVID base is resetting and oncology (Seagen) is the call.